PLCB3 and colorectal carcinoma: Lastly, our data demonstrated that the combination therapy involving cetuximab, si-PLCB3, and a Wnt activator (IM12) contributed to a pronounced down-regulation in CRC cell proliferation, migration, and invasion41.